March 8, 2021

Christopher Anzalone Chief Executive Officer Arrowhead Pharmaceuticals, Inc. 177 E. Colorado Blvd, Suite 700 Pasadena, California 91105

Re: Arrowhead Pharmaceuticals, Inc. fiscal year ended September 30, 2020 2020 File No. 001-38042

Dear Mr. Anzalone:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding

any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences